Lawrence Fusco, MD
Internal Medicine · Reidsville, NCNPI 1700868890
Payments from drug & device makers
Across 217 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$434
- AbbVie$364
- Boehringer Ingelheim$353
- Amgen$216
- Bayer$212
- Esperion Therapeutics, Inc.$202
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $434 |
| AbbVie | 22 | $364 |
| Boehringer Ingelheim | 20 | $353 |
| Amgen | 14 | $216 |
| Bayer | 13 | $212 |
| Esperion Therapeutics, Inc. | 12 | $202 |
| Pfizer | 11 | $196 |
| Novo Nordisk | 9 | $143 |
| Sanofi-aventis U.S. LLC | 9 | $137 |
| AstraZeneca | 8 | $126 |
| Sunovion Pharmaceuticals Inc. | 7 | $101 |
| GSK | 5 | $89 |
| Sanofi Pasteur Inc. | 4 | $85 |
| Forte Bio-pharma LLC | 2 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $68 |
| Amarin Pharma, Inc. | 4 | $63 |
| Dexcom, Inc. | 3 | $62 |
| Merck | 4 | $61 |
| Sumitomo Pharma America, Inc. | 3 | $60 |
| Johnson & Johnson | 5 | $60 |
| Novartis | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Exact Sciences | 3 | $47 |
| Abbott | 2 | $45 |
| VBI Vaccine (delaware) Inc. | 3 | $44 |
| Medtronic | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Organogenesis Inc. | 1 | $22 |
| Corium, LLC | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $16 |
| United Therapeutics Corporation | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$3,627 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 206 | $173,237 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $72,198 |
| OzempicSemaglutide | 65 | $61,393 |
| ZenpepLipase/Protease/Amylase | 11 | $59,382 |
| JanuviaSitagliptin Phosphate | 52 | $56,544 |
| JardianceEmpagliflozin | 55 | $52,508 |
| XareltoRivaroxaban | 46 | $45,930 |
| CreonLipase/Protease/Amylase | 12 | $45,114 |
| LinzessLinaclotide | 58 | $40,189 |
| OxycontinOxycodone Hcl | 22 | $35,917 |
| MounjaroTirzepatide | 30 | $31,814 |
| Oxycodone Hcl | 975 | $31,406 |
| FarxigaDapagliflozin Propanediol | 28 | $30,896 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 623 | $25,494 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $23,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $196 | $173,237206 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $89 | $106,553191 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat | $353 | $100,481118 claims |
| AbbVieCreon, Linzess, Savella | $364 | $96,35693 claims |
| Novo NordiskOzempic, Rybelsus | $143 | $75,44080 claims |
| MerckJanuvia, Belsomra | $61 | $68,32175 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $126 | $53,91264 claims |
| Johnson & JohnsonXarelto | $60 | $45,93046 claims |
| Lilly USA, LLCMounjaro | $434 | $31,81430 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $17 | $17,84335 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $17,32616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Reidsville
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.